Mercury Laboratories Limited (BOM:538964)

India flag India · Delayed Price · Currency is INR
792.30
+2.30 (0.29%)
At close: Mar 4, 2026
Market Cap950.76M -10.8%
Revenue (ttm)761.53M +6.0%
Net Income47.19M +19.6%
EPS39.31 +19.6%
Shares Out1.20M
PE Ratio20.15
Forward PEn/a
Dividend3.50 (0.44%)
Ex-Dividend DateAug 6, 2025
Volume109
Average Volume57
Open799.90
Previous Close790.00
Day's Range792.00 - 887.95
52-Week Range736.00 - 976.00
Beta0.33
RSI46.29
Earnings DateFeb 11, 2026

About Mercury Laboratories

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergi... [Read more]

Industry Pharmaceutical Preparations
Founded 1962
Employees 503
Stock Exchange Bombay Stock Exchange
Ticker Symbol 538964
Full Company Profile

Financial Performance

In fiscal year 2025, Mercury Laboratories's revenue was 751.01 million, a decrease of -0.61% compared to the previous year's 755.59 million. Earnings were 31.45 million, a decrease of -44.38%.

Financial Statements